WO2008105260A1 - 下肢切断手術の予後を改善する治療剤 - Google Patents
下肢切断手術の予後を改善する治療剤 Download PDFInfo
- Publication number
- WO2008105260A1 WO2008105260A1 PCT/JP2008/052694 JP2008052694W WO2008105260A1 WO 2008105260 A1 WO2008105260 A1 WO 2008105260A1 JP 2008052694 W JP2008052694 W JP 2008052694W WO 2008105260 A1 WO2008105260 A1 WO 2008105260A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- ameliorating
- prognosis
- lower limb
- limb amputation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940124597 therapeutic agent Drugs 0.000 title abstract 4
- 238000011542 limb amputation Methods 0.000 title abstract 2
- 210000003141 lower extremity Anatomy 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 title abstract 2
- 238000001356 surgical procedure Methods 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 abstract 1
- 150000003165 prostaglandin E1 derivatives Chemical class 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
重症末梢動脈閉塞症に起因する下肢切断手術の予後を改善する治療剤を提供することであり、次式（Ｉ）：
で示されるプロスタグランジンＥ１（ＰＧＥ１）誘導体（ＡＳ－０１３）を有効成分とする重症末梢動脈閉塞症に起因する下肢切断手術の予後を改善する治療剤であり、具体的には、静脈内投与用製剤又は局所投与用製剤の形態にある治療剤であって、より好ましくは、該注射用製剤が脂肪粒子中に有効成分であるＡＳ－０１３を包埋させたリポ化製剤である、重症末梢動脈閉塞症に起因する下肢切断手術の予後を改善する治療剤である。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008800063978A CN101622003B (zh) | 2007-02-28 | 2008-02-19 | 改善下肢截肢手术的预后的治疗剂 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-049363 | 2007-02-28 | ||
| JP2007049363 | 2007-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008105260A1 true WO2008105260A1 (ja) | 2008-09-04 |
Family
ID=39721096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/052694 WO2008105260A1 (ja) | 2007-02-28 | 2008-02-19 | 下肢切断手術の予後を改善する治療剤 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101622003B (ja) |
| WO (1) | WO2008105260A1 (ja) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0710833A (ja) * | 1991-04-16 | 1995-01-13 | Yutaka Mizushima | プロスタグランジン類縁体、その脂肪乳剤およびその用途 |
| WO1999009992A1 (fr) * | 1997-08-27 | 1999-03-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Promoteurs de neovascularisation |
| WO1999011268A1 (fr) * | 1997-08-28 | 1999-03-11 | Yoshitomi Pharmaceutical Industries, Ltd. | Agents promoteurs et agents potentialisateurs de la neovascularisation |
-
2008
- 2008-02-19 WO PCT/JP2008/052694 patent/WO2008105260A1/ja active Application Filing
- 2008-02-19 CN CN2008800063978A patent/CN101622003B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0710833A (ja) * | 1991-04-16 | 1995-01-13 | Yutaka Mizushima | プロスタグランジン類縁体、その脂肪乳剤およびその用途 |
| WO1999009992A1 (fr) * | 1997-08-27 | 1999-03-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Promoteurs de neovascularisation |
| WO1999011268A1 (fr) * | 1997-08-28 | 1999-03-11 | Yoshitomi Pharmaceutical Industries, Ltd. | Agents promoteurs et agents potentialisateurs de la neovascularisation |
Non-Patent Citations (1)
| Title |
|---|
| ITO M.: "Heisokusei Domyaku Kokasho -Gainen.Bunrui.Shindan.Chiryo-", SHINJIDAI NO TONYOBYOGAKU (4) - BYOIN.SHINDAN.CHIRYO KENKYU NO SHINPO-, KABUSHIKI KASIHA NIPPON RINSHOSHA, 28 October 2002 (2002-10-28), pages 334 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101622003A (zh) | 2010-01-06 |
| CN101622003B (zh) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
| WO2007017135A3 (en) | Process for the preparation of olmesartan medoxomil | |
| WO2008027557A3 (en) | Topiramate compositions and methods of enhancing its bioavailability | |
| EP1834637A4 (en) | COMPOSITION FOR THE PREVENTION / TREATMENT OF DISEASES THROUGH FREE RADICALS | |
| WO2008069941A3 (en) | Modified release ibuprofen solid oral dosage form | |
| WO2010088000A3 (en) | Antifibrotic compounds and uses thereof | |
| AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
| WO2012021107A3 (en) | A liposomal formulation for ocular drug delivery | |
| UA96575C2 (en) | Process for the preparation of olmesartan medoxomil | |
| BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
| WO2009028605A1 (ja) | 抗がん剤による末梢神経障害の予防又は軽減剤 | |
| BR0210293A (pt) | Uma preparação farmacêutica aquosa de cilostazol para utilização parenteral | |
| WO2012012305A3 (en) | Combination therapy using a ruthenium complex | |
| WO2008008701A3 (en) | Substituted cyclopentane derivatives as therapeutic agents | |
| WO2010075315A3 (en) | Topical formulations of flap inhibitors for administration to an eye | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| WO2008133297A1 (ja) | ジスキネジアの治療または予防剤 | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| EA022988B9 (ru) | Соединения фенилкетонкарбоксилата и их фармацевтическое применение | |
| WO2011049979A3 (en) | Injectable formulations for intra- articular or peri-articular administration | |
| PH12013500711A1 (en) | Acylbenzene derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200880006397.8 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08711518 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08711518 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |